Journal article
Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience
A Fasano, A Antonini, R Katzenschlager, P Krack, P Odin, AH Evans, T Foltynie, J Volkmann, M Merello
Movement Disorders Clinical Practice | WILEY | Published : 2020
DOI: 10.1002/mdc3.12965
Abstract
Background: Although the COVID-19 pandemic is affecting a relatively small proportion of the global population, its effects have already reached everyone. The pandemic has the potential to differentially disadvantage chronically ill patients, including those with Parkinson's disease (PD). The first health care reaction has been to limit access to clinics and neurology wards to preserve fragile patients with PD from being infected. In some regions, the shortage of medical staff has also forced movement disorders neurologists to provide care for patients with COVID-19. Objective: To share the experience of various movement disorder neurologists operating in different world regions and provide ..
View full abstractGrants
Funding Acknowledgements
A.F. received honoraria and research support from Abbvie, Abbott, Boston Scientific, and Medtronic. A.A. received honoraria from AbbVie and Neuroderm and research support from Chiesi Pharmaceuticals. R.K. has received honoraria from AbbVie, Britannia, Ever Pharma, and Stada and research grants from Britannia and Stada. P.K. reports grants from Boston Scientific and Aleva and lecturing fees paid to the employing institution from Boston Scientific. P.O. has received honoraria and research support from AbbVie, Britannia, and Nordic Infucare. A.H.E. received honoraria from AbbVie, Britannia, and Abbott. T.F. has received honoraria from Boston Scientific. J.V. reports grants and lecturing fees from Boston Scientific and advisory fees paid by Boston Scientific, Medtronic, and Newronika. M.M. reports grants and lecturing fees from St. Jude Medical/Abbott.